Link Biologics

Link Biologics is a preclinical-stage biotechnology company developing TSG-6-based drugs to transform outcomes in inflammatory and tissue-degenerative conditions.

TSG-6 is an endogenous human protein known for its diverse tissue-protective and anti-inflammatory properties. It reduces inflammation through multiple mechanisms, limits tissue injury, and promotes rapid healing and repair without fibrosis. Additionally, TSG-6 mediates many of the immunomodulatory and regenerative effects of human mesenchymal stem cells (MSCs). This discovery has generated extensive research into the therapeutic benefits of recombinant human full-length TSG-6 protein (rhTSG-6) across numerous models of inflammatory and degenerative diseases[1].